LO ÚLTIMO EN ANTIDEPRESIVOS ► Genomics|Features|Antidepressants [idioma inglés únicamente]

Genomics|Features|Antidepressants

Antidepressants

Antidepressants, Pharmacogenomics and Public Health - May 4, 2015

CDC and Related Info

• Pharmacogenomic testing for dose adjustment of selected antidepressants
• Genes reported in relation to antidepressant, including genomewide association studies via theHuGE Navigator

Genome-wide association studies in pharmacogenomics of antidepressants.
Lin E et al.Pharmacogenomics2015 Apr (5) 555-66

The efficacies and toxicities of antidepressant drugs in clinics, building the relationship between chemo-genetics and socio-environments.
Lu DY et al. Cent Nerv Syst Agents Med Chem 2015 Apr 28.

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.
Biernacka JM et al. Transl Psychiatry 2015 e553

RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response.
Hennings JM et al. Transl Psychiatry 2015 e538

Identifying genetic loci associated with antidepressant drug response with drug-gene interaction models in a population-based study.
Noordam R et al. J Psychiatr Res 2015 Mar 31-7

Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders.
Helton SG et al. Pharmacogenomics 2015 Apr (5) 541-53

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
Hicks J K et al. Clin. Pharmacol. Ther. 2013 May (5) 402-8

CPIC dosing guideline for amitriptyline and CYP2C19, CYP2D6
The CPIC Dosing Guideline for amitriptyline recommends an alternative drug for CYP2D6 or CYP2C19 ultrarapid metabolizers and for CYP2D6 poor metabolizers. Consider a 50% dose reduction for CYP2C19 poor metabolizers and a 25% dose reduction for CYP2D6 intermediate metabolizers, 2013

Pharmacogenomic testing for dose adjustment of selected antidepressants
CDC Tier-2 classification (under psychiatry)

Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
Altar C A et al. Pharmacogenomics J. 2015 Feb 17.

Identifying genetic loci associated with antidepressant drug response with drug-gene interaction models in a population-based study.
Noordam Raymond et al. J Psychiatr Res 2015 Jan 20.

Genetic determinants of selective serotonin reuptake inhibitor related sexual dysfunction.
Stevenson James M et al. Pharmacogenomics 2014 Nov (14) 1791-1806

Genetic prediction of antidepressant drug response and nonresponse in Korean patients.
Lim Shinn-Won et al. PLoS ONE 2014 (9) e107098

Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans.
Wong Ma-Li et al. Am J Psychiatry 2014 Sep 15.

Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians.
Zai Gwyneth et al. Pharmacogenomics 2014 Jun (8) 1147-57

Understanding the pharmacogenetics of selective serotonin reuptake inhibitors.
Fabbri Chiara et al. Expert Opin Drug Metab Toxicol 2014 Aug (8) 1093-118

From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.
Fabbri Chiara et al. Can J Psychiatry 2014 Feb (2) 62-75

Is there a role for antidepressant and antipsychotic pharmacogenetics in clinical practice in 2014?
Mulsant Benoit H et al. Can J Psychiatry 2014 Feb (2) 59-61

Check out genes and genomewide association studies reported in relation to antidepressant use and outcomes, from the HUGE Navigator

Check out genetic tests related to selective serotonin reuptake inhibitor toxicity, from the NIH Genetic Testing Registry